The Zhitong Finance App learned that Rebang Pharmaceutical-B (09637) was more than 6% higher. As of press release, it rose 6.70% to HK$18, with a turnover of HK$1,027,800.

According to the news, Rebang Pharmaceutical announced that the company's board of directors has decided to buy back the company's H shares from time to time on the Stock Exchange's open market in accordance with the general authorization approved at the extraordinary shareholders' meeting, with a total amount not exceeding HK$100 million. The company intends to use its own financial resources to fund share repurchases.

Notably, Peking University Hospital recently announced that its new drug clinical trial application for AP308/PKU308, a new drug jointly developed by the Department of Nephrology and Rebang Pharmaceutical to treat IgA nephropathy, has been approved by the US FDA and is about to enter the first human clinical research phase. On September 28, Shanghai Libang Pharmaceutical Technology Co., Ltd.'s application for injectable AP308 was accepted by the Drug Review Center of the State Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.